openPR Logo
Press release

Marinomed Biotechnologie GmbH: New investment boosts global expansion / innovation

Marinomed Biotechnologie GmbH will boost the successful expansion of its business activities with new investments. The Austrian investment fund "aws Mittelstandsfonds" is acquiring a share in the company and is providing significant financial means. The fund management was impressed with the successful international market entry of Marinomed's treatments for cold and influenza-like diseases. By further investing, the global roll-out of these products will be accelerated. At the same time, the company will use the investment to intensify the development of further products for viral infections of the respiratory system based on the proprietary MAVIREX© technology platform.

The Vienna-based biotech company Marinomed Biotechnologie GmbH announced today that the Austrian investment fund "aws Mittelstandsfonds" acquired a share in the company. The success of the biotech company is especially based on its proprietary MAVIREX© technology platform.

For Dr. Andreas Grassauer, CEO and co-founder of Marinomed, the interest of the renowned "aws Mittelstandsfonds" confirms the success of the company: "Nasal sprays developed by Marinomed have been approved in 48 countries and these OTC products are well in demand. Our forthcoming investment will accelerate this global market entry. Simultaneously we will continue our focused development of innovative products and thus fill our pipeline even further."

The international success of the company is based on the patented MAVIREX© technology platform. This contributed to the development of Carragelose®, a red algae derived polymer with exceptionally strong effects against respiratory viral infections. Carragelose® works by coating viruses, thereby preventing them from attaching to and penetrating the cells of the mucous membranes. In addition, the properties of the polymer provide a soothing and protective film of moisture on the mucous membranes. Currently, Marinomed is exploiting the potential of Carragelose® with a series of nasal sprays and lozenges that act against respiratory viruses. The efficacy of Carragelose® was convincingly demonstrated in several clinical trials with more than 450 patients.

In due course, the company will extend its Carragelose®-based product range by offering OTC throat sprays that will supplement the already successfully marketed nasal sprays and lozenges. Commenting on the further development of the company's product pipeline, Dr. Grassauer says: "An important focus of our development activities are combination products that combine several active compounds for the treatment of viral infections. This enhances the efficacy of the therapy and such concepts are well sought after." Owing to the investment by the "aws Mittelstandsfonds", Marinomed will realize these development plans efficiently and quickly. Mag. Karl Lankmayr, CEO of the "aws Mittelstandsfonds" says: "Marinomed is a well-established company in Vienna that offers a successful product range. As Austria's leading equity fund we support with our investment both Marinomed's research and the continuation of the company's international expansion. In doing so, we also support the growth of Austrian suppliers and thus the entire Austrian biopharmaceutical industry."

About Marinomed Biotechnologie GmbH (as of October 2015)
Marinomed Biotechnologie GmbH, headquartered in Vienna, Austria, is focused on the discovery and development of highly innovative therapies for respiratory diseases. The company has developed MAVIREX©, a technology platform that targets more than 200 different virus strains based on Carragelose®, a naturally derived, sulphated galactose polymer from red seaweed with unique properties for therapies of viral infections of the respiratory system. The technology has been successfully commercialized with three nasal sprays for respiratory infections and lozenges launched internationally into the OTC market. Marinomed Biotechnologie GmbH was founded in 2006 as a spin-off from the Veterinary University Vienna. For more information, please visit www.marinomed.com.

Contact Marinomed:
Dr. Eva Prieschl-Grassauer
Chief Scientific Officer
Veterinärplatz 1
1210 Vienna, Austria
T +43 / 1 / 250 77 - 4460
E eva.prieschl@marinomed.com
W http://www.marinomed.com

Copy Editing & Distribution:
PR&D – Public Relations for Research & Education
Mariannengasse 8
1090 Vienna, Austria
T +43 / 1 / 505 70 44
E contact@prd.at
W http://www.prd.at

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Marinomed Biotechnologie GmbH: New investment boosts global expansion / innovation here

News-ID: 317489 • Views:

More Releases from Marinomed Biotechnologie GmbH

Viennese biotech company Marinomed demonstrates the benefits of its patented Mar …
• Solubilization of the immunomodulator tacrolimus up to 200 times greater using Marinosolv® • Bioavailability in the eye up to 15 times higher under laboratory conditions when compared to commercially available alternative treatments • Findings published in the European Journal of Pharmaceutics and Biopharmaceutics • Clinical trial for Tacrosolv, a tacrolimus-based product candidate against allergic conjunctivitis, planned for 2019 Vienna, 28 November 2018 – Marinomed Biotech AG (Marinomed) – an established Viennese biopharmaceutical company
Marinomed Biotechnologie GmbH: French Nicox S.A. successfully bids for anti-vira …
Vienna – Marinomed Biotechnologie GmbH agreed to sell its promising anti-viral eye drop program to Nicox S.A. of France. The France-based international ophthalmic company acquires the entire program as well as all associated rights, data, contracts and information. In return Marinomed will receive up to € 5.3 Mio. The anti-viral eye drop program of Marinomed derives from the successful technology platform Mavirex® which exploits anti-viral effects of polymers from red
Marinomed Biotechnologie GmbH: Pharma Company Acquires Rights to Antiviral Produ …
MAVIREX® technology is the basis for five products against viral respiratory infections The rights to five medical products of the Viennese biotech company Marinomed have now been licensed to an international pharmaceutical company for the Chinese market. Besides three antiviral nasal sprays against common cold, influenza and colds in children, the deal also includes the two newest products from Marinomed: antiviral lozenges and a throat spray against viral throat infections.

All 4 Releases


More Releases for Austria

Austria Agriculture Market | Austria Agriculture Industry | Austria Agriculture …
The share of Austria agriculture within the Austrian economy declined steady afterward World War II, agriculture continues to represent a very important part of the economy attributable to its social and political significance. The Chamber of Agriculture rests on an equal level with the chambers of commerce and labour, though its members manufactures solely a fraction of the GDP that industrial and sale able labours produce. Though little, the agricultural sector is
Telecoms, Mobile and Broadband 2018-2023 Austria Market Survey Industry Key Play …
WiseGuyReports.com "Austria - Telecoms, Mobile and Broadband - Statistics and Analyses" report has been added to its Research Database. Scope of the Report: Austria's telcos looking forward to major spectrum auctions for 5G. Austria's telecom market is dominated by the incumbent Telekom Austria and the cableco UPC Austria, though there has been greater competitive pressure in the fixed-line broadband and mobile sectors in recent years. In common with operators elsewhere in Europe,
Austria Telecoms, Mobile and Broadband Market Professional Survey with Industry …
WiseGuyReports.com “Austria - Telecoms, Mobile and Broadband - Statistics and Analyses” report has been added to its Research Database. Scope of the Report: Austria’s telcos looking forward to major spectrum auctions for 5G. Austria’s telecom market is dominated by the incumbent Telekom Austria and the cableco UPC Austria, though there has been greater competitive pressure in the fixed-line broadband and mobile sectors in recent years. In common with operators elsewhere in Europe,
Agrochemicals Market in Austria
ReportsWorldwide has announced the addition of a new report title Austria: Agrochemicals: Market Intelligence (2016-2021) to its growing collection of premium market research reports. The report “Austria: Agrochemicals: Market Intelligence (2016-2021)” provides market intelligence on the different market segments, based on type, active ingredient, formulation, crop, and pest. Market size and forecast (2016-2021) has been provided in terms of both, value (000 USD) and volume (000 KG) in the report. A
Nazi psychology in Austria
The history of academic psychology after the "Anschluss", the annexation of Austria by Germany in 1938, and its role as a discipline used in National Socialist policies is being examined systematically for the first time in a research project supported by the Austrian Science Fund FWF. "It is a sad fact”, says psychologist Gerhard Benetka from the Sigmund Freud University Vienna "that applied psychology flourished during the National Socialist era
Creative Austria meets creative Russia
Euroforum: communicatin ready for the next lap Vienna. On 22nd of October 2009 the advertising association Vienna invites again to the annual Euroforum: communication event, platform for European communication, guaranteeing an interesting mix of “connecting businesses and communications”. The Event takes place in Studio 44, Vienna. Focus point Russia (Moscow, St. Petersburg and Sotschi) The main goal of the Euroforum is to promote and establish business relations and synergies between